Acute respiratory failure due to eosinophilic pneumonia following pneumococcal vaccination

Hum Vaccin Immunother. 2019;15(12):2914-2916. doi: 10.1080/21645515.2019.1631134. Epub 2019 Jun 26.

Abstract

A 68-year-old woman under maintenance hemodialysis was admitted to our hospital with fever and dyspnea that had developed two days after the second vaccination with the 23-valent pneumococcal polysaccharide vaccine (PPV23). She had received the first vaccination with PPV23 five years earlier without any complications. Chest X-ray and computed tomography (CT) showed bilateral diffuse infiltrative and ground glass opacities. Bronchoalveolar lavage (BAL) revealed an abundance of eosinophils. A positive test result for PPV23 was obtained in the drug lymphocyte stimulation test. The patient was diagnosed as having eosinophilic pneumonia caused by the pneumococcal vaccination and was successfully treated by 3-week's administration of a steroid. No disease recurrence was observed at the three-month follow-up. Thus, EP is a rare, but life-threating condition following pneumococcal vaccination.

Keywords: Pneumococcal vaccine; eosinophilic pneumonia; respiratory insufficiency.

Publication types

  • Case Reports

MeSH terms

  • Acute Disease
  • Aged
  • Female
  • Humans
  • Pneumococcal Vaccines / adverse effects*
  • Pulmonary Eosinophilia / chemically induced*
  • Pulmonary Eosinophilia / diagnostic imaging
  • Pulmonary Eosinophilia / drug therapy
  • Steroids / therapeutic use
  • Tomography, X-Ray Computed
  • Treatment Outcome
  • Vaccination / adverse effects*

Substances

  • 23-valent pneumococcal capsular polysaccharide vaccine
  • Pneumococcal Vaccines
  • Steroids